Clinical trials
Acute Hospitalization clinical trials
Below are recruiting acute hospitalization clinical trials, each written for real people, not researchers. We’re tracking 987 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03788512Recruiting
Registry study for recent stroke/TIA with heart artery disease
This study enrolls people who recently had an ischemic stroke or a TIA (a “mini-stroke”) and also have evidence of narrowed heart arteries. It collects information to better understand how brain and heart artery disease occur together and may guide future care.
Beijing, BJAges 18–85 - NCT05704166RecruitingPhase 2
Pirfenidone to prevent lung injury after breast radiation
This trial tests whether pirfenidone, a medication, can prevent acute lung injury caused by radiation therapy in people with breast cancer. You may be randomly assigned to pirfenidone or a placebo (inactive pill) to see which better protects the lungs during and after radiation.
Fuzhou, FujianAges 18–75 - NCT07182422RecruitingPhase 4
AST-120 for kidney protection after acute kidney injury
This trial tests if the drug AST-120 (Kremezin) can help protect your kidneys and slow down further kidney decline after a recent acute kidney injury. It is for people who had a moderate to severe kidney injury during a hospital stay and now have mild to moderate chronic kidney damage.
TaoyuanAges 18–80 - NCT06649253Recruiting
CD9 Gene and Relapse in Childhood B-ALL Study
This study looks at how a gene called CD9 might affect relapse in children with B-ALL. It involves extra blood or bone marrow tests to understand why some children relapse.
AngersAges birth–17 years - NCT04240834RecruitingPhase 4
Low-dose ticagrelor vs aspirin after heart stent placement
This study compares ticagrelor taken at a lower dose versus regular aspirin to help prevent future heart attacks in people who recently had a stent placed after acute coronary syndrome. You may qualify if you’re considered “high risk” for new blockages or clots and can take dual anti-platelet therapy for 12 months.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07764588Recruiting
Immune cell study after a heart attack
This study looks at how immune cells change in the first few hours after a severe heart attack (STEMI) and how that relates to early scar healing. It may help doctors understand why some patients heal better than others.
ShanghaiAges 18–80 - NCT07275541Recruiting
Platelet test for early kidney rejection diagnosis
This study tests whether a simple blood test that looks at platelet behavior can help doctors diagnose acute rejection after a kidney transplant. Early detection of rejection may lead to faster treatment and better outcomes.
MartinAges 18 years+ - NCT02714387Recruiting
Study of serious complications from non-traumatic blood vessel brain problems
This study follows people who have non-injury (non-traumatic) blood-vessel-related problems in the brain to understand serious complications. It may help researchers identify risks and improve care over time.
AngersAges 15 years+ - NCT07669558Recruiting
Finding the best side-lying position for ARDS after abdominal surgery
This trial uses a special imaging test (electrical impedance tomography) to find the safest side position for patients with lung injury after abdominal surgery in the ICU. It aims to improve oxygen levels and breathing comfort.
ShanghaiAges 18 years+ - NCT04355975Recruiting
Study follow-up outcomes after a lung blood clot
This trial looks at how people do after an acute pulmonary embolism (a blood clot in the lungs). It aims to understand real-world outcomes over follow-up and may help improve how care teams track patients after treatment.
Bern, Canton of BernAges Any age - NCT04554277Recruiting
Blood test-guided care for people hospitalized with heart failure
This study checks whether using a specific blood test (called sST-2) to guide heart-failure treatment leads to better care and outcomes. It may help by tailoring treatment decisions based on your test results.
Montpellier, OccitanieAges 18 years+ - NCT04641286Recruiting
Tracking changes in quick recovery after acute stroke
This study looks at how stroke symptoms and recovery change over time soon after an acute stroke. It may help doctors better predict outcomes and improve care planning for stroke patients.
LondonAges 18 years+ - NCT05376111RecruitingPhase 2
Venetoclax plus azacitidine for newly diagnosed T-ALL
This Phase 2 study tests whether venetoclax combined with azacitidine can treat newly diagnosed T-ALL, a type of leukemia. It may help reduce cancer activity and improve outcomes if you meet the safety and treatment timing requirements.
Suzhou, JiangsuAges 15 years+ - NCT05657652Recruiting
Medicine regimen for relapsed or refractory B-ALL
This trial studies a specific treatment plan (“CAV regimen”) for people with B-cell ALL that has either come back or did not respond to standard treatment. It may help control the leukemia, if you meet the health and safety requirements.
Suzhou, JiangsuAges 15–70 - NCT05805098RecruitingPhase 2/Phase 3
Testing Venetoclax with chemo for newly diagnosed AML
This trial studies whether adding venetoclax to standard induction chemotherapy (homoharringtonine plus cytarabine) can improve outcomes for people with newly diagnosed AML. It mainly looks at people who can safely receive intensive chemotherapy but have certain heart, kidney, or lung limits.
Suzhou, JiangsuAges 18–60 - NCT06064903RecruitingPhase 1/Phase 2
CAR T-cells for children with T-cell leukemia or lymphoma
This trial tests a personalized therapy where your child's own immune cells are modified to find and destroy cancer cells that carry a specific marker called CD7. It is for children and young adults whose T-cell leukemia or lymphoma has come back or not responded to standard treatments.
Rome, RomeAges 6 months–25 years - NCT06254313Recruiting
Studying neutrophils in flu-related lung injury
This trial looks at how a type of white blood cell affects lung inflammation in people with severe influenza. It may help researchers find better treatments for respiratory failure caused by the flu or other infections.
BordeauxAges 18 years+ - NCT06483906RecruitingPhase 2
Study of a drug combo and stem cell transplant for high-risk AML
This trial tests a combination of three drugs (venetoclax, azacitidine, and homoharringtonine) followed by a donor stem cell transplant for people with intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if this approach can improve outcomes for patients who have not been treated before.
Shanghai, Shanghai MunicipalityAges 18–55 - NCT06484647Recruiting
Stenting methods for blocked artery forks
This trial compares two techniques for placing stents in the tricky area where a coronary artery splits into two branches (a bifurcation). The goal is to see which method leads to better blood flow and fewer complications for people with blockages there.
Rivoli, TurinAges 18 years+ - NCT06651866RecruitingPhase 1
Study of D-CMG for older adults with new AML
This trial tests a new drug combination called D-CMG for people aged 60–75 who have just been diagnosed with a type of leukemia (AML) and cannot have standard chemotherapy. The goal is to find a safe and effective dose.
Xiamen, FujianAges 60–75 - NCT06661642Recruiting
Predicting pain after planned surgery
This study looks at whether we can predict how much pain you will feel after surgery. It aims to help doctors better manage pain after your operation.
AalborgAges 18 years+ - NCT06718244RecruitingPhase 2
CNCT19 for B-ALL with minimal remaining cancer after first remission
This trial tests a CAR-T cell therapy (CNCT19) for people with B-cell acute lymphoblastic leukemia (B-ALL) who still have a tiny amount of cancer cells after standard treatment. The goal is to see if this therapy can clear those remaining cancer cells.
Shanghai, Shanghai MunicipalityAges 16–70 - NCT06768138RecruitingPhase 3
Giving clot-busting medicine directly into the brain after successful blood flow restoration
This trial tests whether a clot-busting drug given directly into the brain artery can improve recovery after a major stroke caused by a blockage in the front part of the brain. The study is for people whose blood flow has already been successfully restored with standard treatments.
NancyAges 18 years+ - NCT06946732Recruiting
Acostream for high-risk and intermediate-risk pulmonary embolism
This trial is testing a device (called the Acostream) to break up blood clots in the lungs for people with serious pulmonary embolism who cannot receive standard clot-busting drugs or surgery. It may be an option if you have high-risk or intermediate-risk PE and are between 18 and 85.
Shanghai, Shanghai MunicipalityAges 18–85
Hear when a new Acute Hospitalization trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for acute hospitalization?
- Yes. Clin2 currently lists 987 recruiting acute hospitalization studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a acute hospitalization trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a acute hospitalization trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.